Financials data is unavailable for this security.
View more
Year on year Chugai Pharmaceutical Co Ltd 's revenues fell -11.78% from 1.26tn to 1.11tn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 374.43bn to 325.47bn, a -13.08% decrease.
| Gross margin | 70.48% |
|---|---|
| Net profit margin | 33.87% |
| Operating margin | 47.29% |
| Return on assets | 19.91% |
|---|---|
| Return on equity | 23.20% |
| Return on investment | 22.95% |
More ▼
Cash flow in JPYView more
In 2023, Chugai Pharmaceutical Co Ltd increased its cash reserves by 106.45%, or 236.51bn. The company earned 409.92bn from its operations for a Cash Flow Margin of 36.88%. In addition the company used 37.29bn on investing activities and also paid 139.33bn in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 1,094.71 |
|---|---|
| Tangible book value per share | 1,082.06 |
More ▼
Balance sheet in JPYView more
| Current ratio | 5.89 |
|---|---|
| Quick ratio | 4.80 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in JPY
Year on year, growth in dividends per share increased 2.56% while earnings per share excluding extraordinary items fell by -13.08%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 1.58% |
|---|---|
| Div growth rate (5 year) | 27.23% |
| Payout ratio (TTM) | 34.44% |
| EPS growth(5 years) | 28.59 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 14.90 |
More ▼
